{"id":390670,"date":"2018-05-24T00:00:00","date_gmt":"2018-05-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algopn0001-2018-biopharma-osteoarthritic-pain-treatment-algorithms-claims-data-analysis-us-2018\/"},"modified":"2026-04-17T11:39:09","modified_gmt":"2026-04-17T11:39:09","slug":"algopn0001-2018-biopharma-osteoarthritic-pain-treatment-algorithms-claims-data-analysis-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algopn0001-2018-biopharma-osteoarthritic-pain-treatment-algorithms-claims-data-analysis-us-2018\/","title":{"rendered":"Osteoarthritic Pain | Treatment Algorithms | Claims Data Analysis | US | 2018"},"content":{"rendered":"<p>Osteoarthritic (<abbr title=\"osteoarthritis\">OA<\/abbr>) pain represents the second largest segment of the chronic pain market and is expected to grow, driven by an aging population and the increasing prevalence of obesity. However, a comprehensively effective and tolerable analgesic class alternative has not become available for this indication in nearly two decades. A successful launch of a new analgesic requires a deep understanding of current treatment patterns in this highly generic and <abbr title=\"over-the-counter\">OTC<\/abbr> market. Over the past few years, several new therapies have launched in the <abbr title=\"osteoarthritis\">OA<\/abbr> pain market, providing incremental safety, tolerability, and\/or dosing benefits to overcome the drawbacks of the current standards of care\u2014nonsteroidal anti-inflammatory drugs (<abbr title=\"nonsteroidal anti-inflammatory drug\">NSAID<\/abbr>s) and opioid analgesics\u2014but how have agents in these drug classes, particularly brand-only products, fared in this highly generic market?<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"osteoarthritis\">OA<\/abbr> pain patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"osteoarthritis\">OA<\/abbr> pain patients?<\/li>\n<li>How have novel branded agents such as abuse-deterrent opioid analgesics been integrated into the treatment algorithm?<\/li>\n<li>What perception of <abbr title=\"osteoarthritis\">OA<\/abbr> pain patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"osteoarthritis\">OA<\/abbr> pain patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with <abbr title=\"osteoarthritis\">OA<\/abbr> pain?<\/li>\n<\/ul>\n<p><strong>Product Description <\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em> provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.<\/p>\n<p><strong>Markets covered:<\/strong> United States.<\/p>\n<p><strong>Real-world data:<\/strong> Longitudinal patient-level claims data analysis.<\/p>\n<p><strong>Key companies: <\/strong>Purdue Pharma, Janssen, Collegium Pharmaceuticals, Horizon Pharma, and Pfizer.<\/p>\n<p><strong>Key drugs:\u00a0<\/strong>Hysingla\u00a0<abbr title=\"extended release\">ER<\/abbr>, Nucynta\u00a0<abbr title=\"extended release\">ER<\/abbr>, oxycodone\u00a0<abbr title=\"controlled release\">CR<\/abbr> (OxyContin, generics), Vimovo, Vivlodex, Xtampza\u00a0<abbr title=\"extended release\">ER<\/abbr>, and Zorvolex.<\/p>\n<p><strong>Key analysis provided:<\/strong><\/p>\n<ul>\n<li>Brand use across longitudinal patient sample.<\/li>\n<li>Newly diagnosed patient analysis.<\/li>\n<li>Treatment initiation and progression.<\/li>\n<li>Line of therapy analysis.<\/li>\n<li>Combination therapy analysis.<\/li>\n<li>Source of business for recently treated patients.<\/li>\n<li>Persistency and compliance analysis.<\/li>\n<li>Product-level patient flowcharts.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390670","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-osteoarthritic-pain","biopharma-therapy-areas-osteoarthritis","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390670\/revisions"}],"predecessor-version":[{"id":393794,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390670\/revisions\/393794"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}